University of Hertfordshire

From the same journal

By the same authors

Antithrombotic therapy in diabetes: Which, when 1 and for how long?

Research output: Contribution to journalArticlepeer-review

  • RA Ajjan
  • N Kietsiriroje
  • L Badimon
  • Diana Gorog
  • Dominick J. Angiolillo
  • D Russel
  • Bianca Rocca
  • Robert F. Storey
View graph of relations
Original languageEnglish
JournalEuropean Heart Journal
Publication statusAccepted/In press - 9 Feb 2021

Abstract

Cardiovascular disease remains the main cause of mortality in individuals with diabetes mellitus (DM) and also results in significant morbidity. Premature and more aggressive atherosclerotic disease, coupled with an enhanced thrombotic environment, contributes to the high vascular risk in individuals with DM. This prothrombotic milieu is due to increased platelet activity together with impaired fibrinolysis secondary to quantitative and qualitative changes in coagulation factors. However, management strategies to reduce thrombosis risk
remain largely similar in individuals with and without DM. The current review covers the latest in the field of antithrombotic management in DM. The role of primary vascular prevention is discussed together with options for secondary prevention following an ischaemic event in different clinical scenarios including coronary, cerebrovascular and peripheral artery disease. Antiplatelet therapy combinations as well as combination of antiplatelet and anticoagulant agents are examined in both the acute phase and long-term, including management of individuals with sinus rhythm and those with atrial fibrillation. The difficulties in tailoring therapy according to the variable atherothrombotic risk in different individuals are emphasised, in addition to the varying risk within an individual secondary to DM duration, presence of complications and predisposition to bleeding events. This review provides the reader with an up-to-date guide for antithrombotic management of individuals with DM and highlights gaps in knowledge that represent areas for future research, aiming to improve clinical outcome in this high-risk population.

ID: 24591151